By Jason Derry --
CytRx Corp. has announced that it has
contributed its RNA interference portfolio to RXi Pharmaceuticals Corp. CytRx owns 85% of RXi while the remaining 15%
will be owned by RXi's scientific advisory board. The members of the advisory board, subject to
consent from each member's employer, include Craig C. Mello, Ph.D., Gregory J. Hannon, Ph.D., Tariq M. Rana,
Ph.D., and Michael P. Czech, Ph.D. RXi will focus on developing RNAi therapeutics
for treating human diseases. According
to the press release, Tod Woolf, Ph.D. will be the Chief Executive Officer of
RXi.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments